<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Systemic treatment of metastatic melanoma lacking a BRAF mutation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Systemic treatment of metastatic melanoma lacking a BRAF mutation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Systemic treatment of metastatic melanoma lacking a BRAF mutation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey A Sosman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H177442132"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The most common molecular alteration in patients with metastatic melanoma are mutations in the <em>BRAF</em> gene, in particular <em>BRAF</em> V600 [<a href="#rid1">1-4</a>]. In these patients, <em>BRAF</em> mutation status can subsequently influence management. (See  <a class="medical medical_review" href="/d/html/16540.html" rel="external">"The molecular biology of melanoma"</a> and  <a class="medical medical_review" href="/d/html/85841.html" rel="external">"Overview of the management of advanced cutaneous melanoma"</a>.)</p><p>For patients with metastatic melanoma lacking a <em>BRAF</em> mutation, there have been important advances in systemic therapy, such as checkpoint inhibitor immunotherapy. Available options for immunotherapy include agents that inhibit cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death receptor 1 (PD-1), among others. The principles and biologic mechanism of immunotherapy in the treatment of cancer, including melanoma, is discussed separately. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy"</a>.)</p><p>The approach to systemic therapy in patients with metastatic melanoma lacking a <em>BRAF</em> mutation (ie, <em>BRAF</em> wild-type disease) is reviewed in this topic  (<a class="graphic graphic_algorithm graphicRef105384" href="/d/graphic/105384.html" rel="external">algorithm 1</a>). The management of patients with metastatic melanoma harboring a <em>BRAF</em> or other molecular alterations, adjuvant and neoadjuvant therapy for locally advanced cutaneous melanoma, the surgical management of melanoma, and toxicities associated with checkpoint inhibitor immunotherapy are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7615.html" rel="external">"Adjuvant and neoadjuvant therapy for cutaneous melanoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7620.html" rel="external">"Surgical management of primary cutaneous melanoma or melanoma at other unusual sites"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p></p><p class="headingAnchor" id="H1091433054"><span class="h1">TREATMENT-NAIVE PATIENTS</span><span class="headingEndMark"> — </span>For patients with <em>BRAF</em> wild-type disease, we recommend initial immunotherapy that includes a programmed cell death receptor 1 (PD-1) inhibitor (ie, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>), rather than other systemic agents, including single-agent <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, high-dose interleukin 2 (IL-2), or chemotherapy. Patient eligibility for checkpoint inhibitor immunotherapy is discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Defining immunotherapy eligibility'</a>.)</p><p class="headingAnchor" id="H1361934520"><span class="h2">Benefits of immunotherapy over chemotherapy</span><span class="headingEndMark"> — </span>Systemic therapy using checkpoint inhibitor immunotherapy is established as the preferred initial treatment option in patients with metastatic melanoma compared with chemotherapy. In randomized trials of patients with <em>BRAF</em> wild-type metastatic melanoma, checkpoint inhibitor immunotherapy demonstrated superior overall survival (OS) and progression-free survival (PFS) benefit and comparable toxicity to chemotherapy. As an example, in a randomized phase III trial (CheckMate-066) of treatment-naïve patients with <em>BRAF</em> wild-type metastatic melanoma, single-agent <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> improved OS compared with <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a> (hazard ratio [HR] 0.46) [<a href="#rid5">5</a>]. Data from this trial are further discussed below. (See <a class="local">'Nivolumab'</a> below.)</p><p>In separate randomized trials, compared with chemotherapy, similar benefits for OS were seen with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in treatment-naïve patients [<a href="#rid6">6</a>] and for PFS with single-agent <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> in those with ipilimumab-refractory disease [<a href="#rid7">7,8</a>]. Further details on the use of chemotherapy and high-dose IL-2 in patients with metastatic melanoma are discussed separately. (See  <a class="medical medical_review" href="/d/html/15406.html" rel="external">"Cytotoxic chemotherapy for metastatic melanoma"</a> and  <a class="medical medical_review" href="/d/html/15407.html" rel="external">"Interleukin 2 and experimental immunotherapy approaches for advanced melanoma"</a>.)</p><p class="headingAnchor" id="H2011103238"><span class="h2">Patients with features of aggressive disease</span></p><p class="headingAnchor" id="H2365012211"><span class="h3">Nivolumab plus ipilimumab (preferred)</span><span class="headingEndMark"> — </span>For patients with treatment-naïve metastatic melanoma without a <em>BRAF</em> V600 mutation and aggressive disease, we suggest combination immunotherapy with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef130970" href="/d/graphic/130970.html" rel="external">table 1</a>) rather than a single-agent PD-1 inhibitor or <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a>  (<a class="graphic graphic_algorithm graphicRef105384" href="/d/graphic/105384.html" rel="external">algorithm 1</a>). Clinical features that suggest aggressive disease include elevated lactate dehydrogenase (LDH); acral primary; and brain metastases, liver metastases, and/or other symptomatic systemic metastases [<a href="#rid9">9,10</a>].</p><p>In patients with treatment-naïve advanced or metastatic melanoma (regardless of <em>BRAF</em> status), compared with single-agent <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>, the combination of nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> improved PFS and treatment-free interval, and trended toward improved OS and melanoma-specific survival (MSS). Most of the benefit of the combination relative to nivolumab monotherapy was confined to patients with <em>BRAF</em>-mutant disease. In patients with <em>BRAF</em> wild-type melanoma, relative to nivolumab, there was a nonstatistically significant trend for PFS and OS benefit for nivolumab plus ipilimumab [<a href="#rid11">11,12</a>]. However, both nivolumab plus ipilimumab and single-agent nivolumab improved PFS, OS, and MSS compared with single-agent ipilimumab [<a href="#rid11">11-16</a>]. (See <a class="local">'All patients'</a> below and <a class="local">'BRAF wild-type disease'</a> below.)</p><p>The overall data for <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> also showed a strong advantage over single-agent immunotherapy (either nivolumab or ipilimumab) in extending the time off treatment. These data suggest that nivolumab plus ipilimumab may offer many patients an opportunity for curative-intent therapy [<a href="#rid17">17</a>]. (See <a class="local">'Treatment-free survival'</a> below.)</p><p class="headingAnchor" id="H3136589399"><span class="h4">Dosing considerations</span><span class="headingEndMark"> — </span>We administer <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> (1 mg/kg) in combination with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> (3 mg/kg) every three weeks for four doses, followed by maintenance nivolumab  (<a class="graphic graphic_table graphicRef130970" href="/d/graphic/130970.html" rel="external">table 1</a>).</p><p>Alternative dosing schedules have also been evaluated. Data are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative dosing of </strong><strong>nivolumab</strong><strong> and </strong><strong>ipilimumab</strong> – The standard dosing of this combination is four doses of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> 1 mg/kg plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> 3 mg/kg every three weeks  (<a class="graphic graphic_table graphicRef130970" href="/d/graphic/130970.html" rel="external">table 1</a>). However, four doses of nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every three weeks is an acceptable off-label alternative.</p><p></p><p class="bulletIndent1">In a randomized phase IIIb/IV study (CheckMate 511) of 360 patients with previously untreated, unresectable stage III or IV melanoma, an alternative dosing strategy of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> 3 mg/kg plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> 1 mg/kg reduced toxicity compared with a standard dosing strategy of nivolumab 1 mg/kg plus ipilimumab 3 mg/kg [<a href="#rid18">18,19</a>]. In preliminary results, at median follow-up of 44 months, compared with standard dosing, the alternative dosing decreased treatment-related grade ≥3 adverse events (34 versus 48 percent, odds ratio 0.55, 95% CI 0.36-0.84) [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1">In descriptive analyses, objective response rates, three-year PFS and OS, and median treatment-free intervals were similar between the two treatment arms. However, the study was not adequately powered to confirm noninferiority of the alternative versus the standard dosing regimen. Therefore, clinicians who offer this approach must discuss with patients that this alternative regimen was not evaluated for noninferiority compared with the standard dosing of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Is there a role for reducing the number of doses of </strong><strong>nivolumab</strong><strong> plus </strong><strong>ipilimumab</strong><strong>?</strong> – In patients with advanced or metastatic melanoma, initial data are promising for reducing the number of doses of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> to less than the established standard of four doses. Although preliminary results from a phase II trial suggest that most of the efficacy occurs within the first two doses [<a href="#rid20">20</a>], further randomized trials are needed to identify which patients treated with nivolumab plus ipilimumab are best suited for this approach and confirm that it reduces toxicity without compromising long-term outcomes.</p><p></p><p class="headingAnchor" id="H1426303705"><span class="h4">All patients</span><span class="headingEndMark"> — </span>Based on results from phase I and II studies [<a href="#rid16">16,21</a>], a double-blind, placebo-controlled phase III trial (CheckMate 067) was conducted to evaluate the efficacy of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> or nivolumab alone versus ipilimumab alone [<a href="#rid11">11-14</a>]. In this trial, 945 treatment-naïve patients were randomly assigned to one of the following treatments:</p><p class="bulletIndent1"><span class="glyph">●</span>Combination nivolumab (1 mg/kg every three weeks for four doses) plus ipilimumab (3 mg/kg every three weeks for four doses), followed by nivolumab 3 mg/kg every two weeks</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nivolumab 3 mg/kg every two weeks</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ipilimumab 3 mg/kg every three weeks for four doses</p><p></p><p>PFS and OS were the co-primary endpoints of the trial. The trial was powered to compare each of the nivolumab-containing arms with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, but it was not powered to compare the combination with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> alone.</p><p>For the entire study population, at a minimum follow-up of 6.5 years, objective response rates<strong> </strong>for the combination, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> alone, and <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> alone were 58, 45, and 19 percent, respectively; complete response rates were 23, 19, and 6 percent, respectively [<a href="#rid11">11,12</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nivolumab</strong><strong>-containing arms versus </strong><strong>ipilimumab</strong><strong> alone </strong>– Relative to <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> alone, results for the two nivolumab-containing arms for the entire study population were as follows [<a href="#rid11">11,12</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Progression-free survival </strong>– The 6.5-year PFS rates for the combination and <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> alone were superior (for nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> versus ipilimumab, 34 versus 7 percent, HR 0.42, 95% CI 0.35-0.51; for nivolumab versus ipilimumab, 29 versus 7 percent, HR 0.53, 95% CI 0.44-0.64).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Overall survival </strong>– The 6.5-year OS rates for the combination and <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> alone were also superior (for nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> versus ipilimumab, 49 versus 23 percent, HR 0.52, 95% CI 0.43-0.64; for nivolumab versus ipilimumab, 42 versus 23 percent, HR 0.63, 95% CI 0.52-0.76).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Melanoma-specific survival </strong>– In a post-hoc analysis, the 6.5-year MSS rates for the combination and <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> alone were also superior (for nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> versus ipilimumab, 56 versus 27 percent, HR 0.48, 95% CI 0.39-0.60; for nivolumab versus ipilimumab, 48 versus 27 percent, HR 0.59, 95% CI 0.48-0.73).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nivolumab</strong><strong> plus </strong><strong>ipilimumab</strong><strong> versus </strong><strong>nivolumab</strong><strong> alone </strong>– Relative to <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> alone, results for the combination for the entire study population were as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Progression-free survival </strong>– The 6.5-year PFS was increased with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> compared with nivolumab alone (34 versus 29 percent, HR 0.79, 95% CI 0.65-0.97).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Overall survival </strong>– The 6.5-year OS for <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> was 49 percent, compared with 42 percent with nivolumab (HR 0.84, 95% CI 0.67-1.04).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Melanoma-specific survival</strong> – In a post-hoc analysis, the 6.5-year MSS for <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> was 56 percent, compared with 48 percent with nivolumab (HR 0.81, 95% CI 0.64-1.03) [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H2326235229"><span class="h4">BRAF wild-type disease</span><span class="headingEndMark"> — </span>In results from CheckMate-067, among the subgroup of 644 patients with <em>BRAF</em> wild-type disease, at minimum follow-up of 6.5 years, the combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> improved PFS and OS relative to ipilimumab [<a href="#rid11">11,12</a>], similar to the results seen for the entire study population. (See <a class="local">'All patients'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nivolumab</strong><strong>-containing arms versus </strong><strong>ipilimumab</strong><strong> alone </strong>– Relative to <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> alone, results for the two nivolumab-containing arms for those with <em>BRAF</em> wild-type disease were as follows [<a href="#rid11">11,12</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Progression-free survival </strong>– The 6.5-year PFS rates for the combination and <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> alone were superior (for nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> versus ipilimumab, 33 versus 6 percent, HR 0.41, 95% CI 0.33-0.52; for nivolumab versus ipilimumab, 31 versus 6 percent, HR 0.47, 95% CI 0.38-0.59).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Overall survival </strong>– The 6.5-year OS rates for the combination and <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> alone were also superior (for nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> versus ipilimumab, 46 versus 22 percent, HR 0.58, 95% CI 0.45-0.74; for nivolumab versus ipilimumab, 42 versus 22 percent, HR 0.63, 95% CI 0.50-0.80).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nivolumab</strong><strong> plus </strong><strong>ipilimumab</strong><strong> versus </strong><strong>nivolumab</strong><strong> alone </strong>– Relative to <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> alone, the combination of nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> demonstrated a nonstatistically significant trend toward PFS and OS benefit for those with <em>BRAF</em> wild-type disease [<a href="#rid11">11,12</a>]. However, this benefit may still be particularly relevant for patients with aggressive disease (eg, brain metastases, elevated LDH, symptomatic metastatic disease) where a salvage regimen may not be available.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Progression-free survival </strong>– The 6.5-year PFS with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> was 33 percent, compared with 31 percent for nivolumab alone (HR 0.88, 95% CI 0.69-1.12).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Overall survival </strong>– The 6.5-year OS for <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> was 46 percent, compared with 42 percent with nivolumab (HR 0.92, 95% CI 0.71-1.18).</p><p></p><p class="headingAnchor" id="H963618493"><span class="h4">Aggressive disease and other populations</span><span class="headingEndMark"> — </span>In subgroup analyses, certain subsets of patients (eg, those with clinical features suggesting aggressive disease, <em>BRAF</em>-mutant tumors) appeared to derive greater benefit with the combination relative to <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated LDH </strong>– Approximately one-third of patients with elevated LDH, a risk factor for aggressive disease, also benefit from the combination of <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> plus <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>. In these patients, five-year OS and PFS were numerically higher for those treated with nivolumab plus ipilimumab compared with nivolumab alone (five-year OS 38 versus 28 percent, HR 0.82, 95% CI 0.52-1.13; five-year PFS 28 versus 18 percent, HR 0.77, 95% CI 0.56-1.05) [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Brain metastases </strong>– The efficacy of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in patients with brain metastases are discussed separately. (See  <a class="medical medical_review" href="/d/html/7611.html" rel="external">"Management of brain metastases in melanoma", section on 'Nivolumab plus ipilimumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>BRAF</em></strong><strong>-mutant tumors </strong>– The magnitude of benefit for <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> appeared to be greater among those<strong> </strong>with<em> BRAF</em>-mutated tumors. These data are discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Nivolumab plus ipilimumab (preferred)'</a>.)</p><p></p><p class="headingAnchor" id="H2516709703"><span class="h4">Toxicity</span><span class="headingEndMark"> — </span>Treatment-related toxicities and the need for treatment discontinuation are more frequent for the combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> compared with either nivolumab or ipilimumab as single agents [<a href="#rid22">22-24</a>]. Patients receiving this combination should be offered appropriate monitoring and treatment for immune-related adverse events. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p>In extended follow-up of the phase III CheckMate 067 trial, rates of grade ≥3 treatment-related adverse events for the combination, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> alone, and <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> alone were 59, 24, and 28 percent, respectively, with no new toxicity signals noted [<a href="#rid11">11,12</a>]. Gastrointestinal toxicity was the most common grade ≥3 adverse event (15, 4, and 12 percent for combination therapy, nivolumab alone and ipilimumab alone, respectively) [<a href="#rid11">11</a>].</p><p>Grade ≥3 treatment-related adverse events led to discontinuation in 31, 8, and 13 percent of patients treated with the combination, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> alone, or <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> alone, respectively [<a href="#rid11">11,12</a>]. However, other data suggest that discontinuing nivolumab plus ipilimumab due to adverse events is not associated with worse clinical outcomes [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Relationship between immunotherapy toxicities and efficacy'</a>.)</p><p>Decision-making regarding resumption of immunotherapy after immune-related toxicities is discussed separately. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Retreatment after prior toxicity'</a>.)</p><p class="headingAnchor" id="H4233328411"><span class="h3">Nivolumab-relatlimab</span><span class="headingEndMark"> — </span>For patients with aggressive disease who are anticipated to not tolerate the toxicities of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, we suggest <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a> rather than single-agent PD-1 inhibitors. In a phase III trial (RELATIVITY-047), nivolumab-relatlimab improved PFS over single-agent nivolumab [<a href="#rid25">25</a>] and had a more favorable toxicity profile compared with that reported for nivolumab plus ipilimumab in other studies [<a href="#rid11">11-14</a>]. (See <a class="local">'All patients'</a> below.)</p><p class="headingAnchor" id="H1926074258"><span class="h4">Dosing considerations</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">Nivolumab-relatlimab</a> is a fixed-dose combination of two IgG4 kappa monoclonal antibodies, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> and relatlimab. For adult and pediatric patients 12 years of age or older who weigh at least 40 kg, 480 mg of nivolumab and 160 mg of relatlimab are administered intravenously and simultaneously every four weeks until disease progression or unacceptable toxicity [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H807823312"><span class="h4">All patients</span><span class="headingEndMark"> — </span>Relatlimab is a human IgG4 LAG-3-blocking antibody that restores effector function of exhausted T cells. Further details on the mechanism of action for relatlimab are discussed separately. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'LAG3'</a>.)</p><p><a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">Nivolumab-relatlimab</a> was evaluated in a double-blind phase III trial (RELATIVITY-047) of 714 patients with treatment-naive advanced melanoma [<a href="#rid25">25,27</a>]. At median follow-up of 19 months, compared with single-agent <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>, nivolumab-relatlimab demonstrated the following [<a href="#rid27">27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Improved PFS (median 10 versus 5 months, two-year PFS 39 versus 29 percent, HR 0.78, 95% CI 0.64-0.94). PFS benefit was also seen across multiple subgroups indicating high-risk disease (ie, elevated LDH and acral primary) [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A non-statistically significant trend towards improved OS, which would be clinically meaningful if true (median not reached versus 34 months, three-year OS 56 versus 48 percent, HR 0.80, 95% CI 0.64-1.01).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher objective response rates (43 versus 33 percent) and similar complete response (CR) rates (16 versus 14 percent).</p><p></p><p><a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">Nivolumab-relatlimab</a> had a more favorable toxicity profile compared with that reported in other studies for <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> [<a href="#rid11">11-14,25</a>]. Grade ≥3 toxicities were higher for the combination versus nivolumab alone (21 versus 11 percent); common symptoms of any grade included pruritus, fatigue, rash, arthralgias, hypothyroidism, diarrhea, and vitiligo [<a href="#rid27">27</a>]. Common grade ≥3 immunotherapy-related adverse events (irAEs) for nivolumab-relatlimab included hepatitis (4 percent), adrenal insufficiency (2 percent), rash, diarrhea, nephritis and kidney dysfunction, pneumonitis, and hypophysitis (approximately 1 percent each). Myocarditis occurred more frequently with nivolumab-relatlimab (two versus one percent) and patients were serially monitored with troponins for the first two months of therapy. However, health-related quality of life was similar between nivolumab-relatlimab and nivolumab alone [<a href="#rid28">28</a>].</p><p>Based on these data [<a href="#rid25">25</a>], the US Food and Drug Administration (FDA) approved <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a> for patients with unresectable or metastatic melanoma ages 12 and older [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H1075011023"><span class="h4">BRAF wild-type disease</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">Nivolumab-relatlimab</a> also improved PFS for the subset of patients with <em>BRAF</em> wild-type disease. A randomized phase III trial (RELATIVITY-047) included a subset of 439 patients with <em>BRAF</em> wild-type disease [<a href="#rid25">25</a>]. Among these patients, at median follow-up of 19 months, the combination improved PFS compared with single-agent <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> (HR 0.78, 95% CI 0.61-0.99) [<a href="#rid27">27</a>]. The PFS benefit seen for patients with <em>BRAF</em> wild-type disease was similar to that seen for the entire study population. (See <a class="local">'All patients'</a> above.)</p><p>The efficacy of <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a> in treatment-naïve patients with <em>BRAF</em>-mutant disease is discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Nivolumab-relatlimab'</a>.)</p><p class="headingAnchor" id="H3731789699"><span class="h2">Patients lacking features of aggressive disease</span></p><p class="headingAnchor" id="H2300651039"><span class="h3">Nivolumab-relatlimab (preferred)</span><span class="headingEndMark"> — </span>For patients with treatment-naive <em>BRAF </em>wild-type disease who lack features of aggressive disease, we suggest <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a> rather than single-agent PD-1 inhibitors.</p><p>In subset analyses of a randomized phase III trial (RELATIVITY-047), <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a> improved PFS compared with single-agent <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> in patients without features of aggressive disease. Such patients included those with LDH less than or equal to the upper limit of normal (HR 0.70, 95% CI 0.54-0.91) and cutaneous non-acral disease (HR 0.73, 95% CI 0.57-0.93) [<a href="#rid25">25</a>].</p><p>Further data on the efficacy and toxicity of <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a> in the entire study population are discussed above. (See <a class="local">'Nivolumab-relatlimab'</a> above.)</p><p class="headingAnchor" id="H3195712893"><span class="h3">Pembrolizumab</span><span class="headingEndMark"> — </span>For patients with <em>BRAF </em>wild-type disease and who lack features of aggressive disease, or those who are unable to tolerate the potential toxicities of combination immunotherapy (ie, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> or <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a>), we offer a single-agent PD-1 inhibitor as a suitable alternative  (<a class="graphic graphic_algorithm graphicRef105384" href="/d/graphic/105384.html" rel="external">algorithm 1</a>). Options include <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 2</a>) or nivolumab  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 3</a>). (See <a class="local">'Nivolumab'</a> below.)</p><p class="headingAnchor" id="H153110854"><span class="h4">Dosing considerations</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a> is administered intravenously at <strong>either</strong> 200 mg every three weeks <strong>or</strong> 400 mg every six weeks  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 2</a>). Data from a phase I trial (KEYNOTE-555) and observational studies [<a href="#rid29">29,30</a>] suggest comparable efficacy and safety between the two schedules. In this study, pembrolizumab administered at 400 mg every six weeks was evaluated in a cohort of 100 patients with advanced or metastatic melanoma without prior exposure to immunotherapy [<a href="#rid31">31</a>]. In an interim analysis of 44 patients with median follow-up of approximately seven months, the overall response rate was 39 percent. This was comparable to a response rate of 35 percent calculated from three separate trials previously evaluating pembrolizumab administered every three weeks in a similar population of patients, including KEYNOTE-001, KEYNOTE-006, and KEYNOTE-252 [<a href="#rid32">32,33</a>]. Grade ≥3 toxicities were seen in 11 patients (25 percent), which are also comparable to previous pembrolizumab trials.</p><p>Based on these data, the US Food and Drug Administration (FDA) approved <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> at a dose of 400 mg every six weeks across all approved adult indications, including patients with advanced or metastatic melanoma. Clinicians may offer pembrolizumab on an every-six-week schedule as a convenient and alternative dosing to the every-three-week schedule. Although the studies above only evaluated this schedule in treatment-naïve patients, we consider it to be an acceptable alternative in patients receiving either front-line or subsequent-line therapy with pembrolizumab.</p><p class="headingAnchor" id="H4045844098"><span class="h4">All patients</span><span class="headingEndMark"> — </span>Based on data from early-phase clinical trials [<a href="#rid32">32,34,35</a>] and initial randomized studies of patients with disease refractory to <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> [<a href="#rid7">7,8</a>], the efficacy of single-agent <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> was established in a randomized phase III trial. In this study, pembrolizumab  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 2</a>) improved both PFS and OS relative to ipilimumab among immunotherapy-naïve patients [<a href="#rid36">36-40</a>].</p><p></p><p>In a phase III trial (KEYNOTE-006), 834 patients were randomly assigned to <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> at 10 mg/kg, administered either every two weeks or every three weeks, versus four doses of <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> 3 mg/kg every three weeks. Treatment with pembrolizumab was typically continued for two years in the absence of toxicity or progressive disease. However, patients were allowed, per investigator discretion, to discontinue pembrolizumab after at least six months in the setting of a complete response. Approximately 35 percent of patients had a <em>BRAF</em> V600 mutation, and approximately one-half of these had received prior BRAF or MEK inhibitor therapy. Approximately 3 percent of patients had received prior immunotherapy.</p><p>At a median follow-up of 85 months, relative to <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> demonstrated the following in the entire study population [<a href="#rid40">40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Improved OS (median 33 versus 16 months; seven-year OS 38 versus 25 percent; HR 0.70, 95% CI 0.58-0.83) and PFS (median 9 versus 4 months; seven-year PFS 24 versus 13 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At median follow-up of 58 months, higher objective (42 versus 17 percent) and complete response rates (14 versus 3 percent) [<a href="#rid36">36</a>].</p><p></p><p>In subset analysis, among patients who were naïve to systemic treatment (including immunotherapy, chemotherapy, and/or BRAF/MEK inhibitors), <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> also improved seven-year OS (41 versus 28 percent, HR 0.67, 95% CI 0.53-0.84) and PFS (27 versus 16 percent, HR 0.62, 95% CI 0.50-0.76), relative to <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> [<a href="#rid40">40</a>]. For patients whose tumors did not express programmed death ligand 1 (PD-L1), pembrolizumab did not demonstrate an OS benefit relative to ipilimumab [<a href="#rid41">41</a>].</p><p>Rates of grade ≥3 toxicity were similar between <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> and <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> (17 versus 20 percent), as were treatment-related discontinuation rates (10 versus 9 percent). Pembrolizumab also improved quality of life and global health status in a secondary analysis based on patient-reported outcomes [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H2793553417"><span class="h4">BRAF wild-type disease</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a> also improved OS in patients with <em>BRAF</em> wild-type disease. A randomized phase III trial (KEYNOTE-006) included a subset of 525 patients with <em>BRAF</em> wild-type disease. Among these patients, compared with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, pembrolizumab improved objective response rates (43 versus 16 percent) [<a href="#rid36">36</a>]. At median follow-up of seven year, pembrolizumab also improved OS relative to ipilimumab (median 28 versus 14 months, HR 0.71, 95% CI 0.56-0.89) [<a href="#rid40">40</a>]. The efficacy of pembrolizumab in treatment-naïve patients with <em>BRAF</em>-mutant disease is discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Alternative immunotherapy options'</a>.)</p><p>Other data have also demonstrated activity for <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> among patients with treatment-naïve disease, regardless of <em>BRAF</em> status. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Alternative immunotherapy options'</a>.)</p><p class="headingAnchor" id="H2968840948"><span class="h3">Nivolumab</span><span class="headingEndMark"> — </span>For patients with <em>BRAF</em> wild-type disease who lack features of aggressive disease, or those who are unable to tolerate the potential toxicities of combination immunotherapy (ie, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> or <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a>), we offer a single-agent PD-1 inhibitor as a suitable alternative  (<a class="graphic graphic_algorithm graphicRef105384" href="/d/graphic/105384.html" rel="external">algorithm 1</a>). Options include nivolumab  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 3</a>) and <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 2</a>). (See <a class="local">'Pembrolizumab'</a> above.)</p><p class="headingAnchor" id="H1703663868"><span class="h4">Dosing considerations</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">Nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 3</a>) is administered at either 240 mg as a flat dose every two weeks or 480 mg as a flat dose every four weeks.</p><p>The original approved dose of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> was 3 mg/kg every two weeks based on initial phase III trials. (See <a class="local">'All patients'</a> above and <a class="local">'BRAF wild-type disease'</a> below.) </p><p>The FDA subsequently approved a modified dose of 240 mg as a flat dose every two weeks, which is similar to the 3 mg/kg intravenous dose based on population pharmacokinetics and dose/exposure-response analyses. An alternative schedule of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> 480 mg every four weeks was also approved, based on clinical pharmacology analyses and safety assessments [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H3241727918"><span class="h4">All patients</span><span class="headingEndMark"> — </span>The efficacy of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> compared with nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in all patients with metastatic melanoma is discussed above. (See <a class="local">'Nivolumab plus ipilimumab (preferred)'</a> above.)</p><p class="headingAnchor" id="H874813968"><span class="h4">BRAF wild-type disease</span><span class="headingEndMark"> — </span>Based on data from early-phase clinical trials [<a href="#rid43">43-45</a>] and initial randomized studies in patients with ipilimumab-refractory disease [<a href="#rid46">46</a>], the efficacy of single-agent <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 3</a>) was established in a randomized phase III trial (CheckMate 066). In this study, 418 treatment-naïve patients with <em>BRAF</em> wild-type disease were randomly assigned to nivolumab (3 mg/kg every two weeks) or <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a> (1000 mg/m<sup>2</sup> every three weeks) [<a href="#rid5">5,47,48</a>]. At minimum follow-up of 38 months, compared with dacarbazine, nivolumab improved three-year PFS (32 versus 3 percent, HR 0.42, 95% CI 0.33-0.53), three-year OS (51 versus 22 percent, HR 0.46, 95% CI 0.36-0.59) [<a href="#rid5">5</a>], and objective response rates (43 versus 14 percent).</p><p><a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">Nivolumab</a> has also been compared with nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in patients with metastatic melanoma. Data for those with <em>BRAF</em> wild-type disease are discussed above. (See <a class="local">'Nivolumab plus ipilimumab (preferred)'</a> above.)</p><p>Data for <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> in patients with <em>BRAF</em>-mutant disease are discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Alternative immunotherapy options'</a>.)</p><p class="headingAnchor" id="H1705214003"><span class="h2">What is the optimal duration of immunotherapy?</span></p><p class="headingAnchor" id="H2109083907"><span class="h3">Single-agent immunotherapy</span><span class="headingEndMark"> — </span>For patients with <em>BRAF</em> wild-type metastatic melanoma receiving single-agent PD-1 inhibitor immunotherapy (ie, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> or <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> as monotherapy; or nivolumab as maintenance therapy after combination therapy with nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>) with either a partial response or stable disease, we typically administer treatment for a maximum of two years in the absence of toxicity. However, for those with a complete response, single-agent immunotherapy may be discontinued after at least six months of therapy have been completed if the complete response has been confirmed on at least two sets of restaging imaging studies. This approach is based on the efficacy of pembrolizumab in a randomized phase III trial (KEYNOTE-006) [<a href="#rid36">36</a>] and other studies [<a href="#rid49">49-52</a>]. (See <a class="local">'Pembrolizumab'</a> above.) </p><p>Early-phase clinical trials of both <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> [<a href="#rid32">32,34,35</a>] and <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> [<a href="#rid43">43-45,53</a>] demonstrated the ability of these agents to achieve long-term PFS in a significant number of patients. Subsequent data from a phase III trial (KEYNOTE-006) provided support for discontinuation of pembrolizumab after two years in responding patients, with an option of discontinuation after six months for complete responders. In this trial, at median follow-up of almost five years, among the 19 percent (103 patients) who had completed a two-year course of pembrolizumab, the three-year OS was 94 percent [<a href="#rid36">36</a>]. Among the 44 patients with a complete response, two-year PFS rates were similar to those who continued pembrolizumab for two years and those who discontinued prior to two years but after at least six months (85 versus 86 percent, respectively).</p><p>The duration of immunotherapy among patients with concurrent successful treatment of intracranial metastases is discussed separately. (See  <a class="medical medical_review" href="/d/html/7611.html" rel="external">"Management of brain metastases in melanoma", section on 'Duration of therapy after complete response'</a>.)</p><p class="headingAnchor" id="H3244367150"><span class="h3">Nivolumab-relatlimab</span><span class="headingEndMark"> — </span>There are no data on the optimal duration of <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a> based on disease response, or switching to single-agent <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> in patients who experience immune-related adverse events. Nivolumab-relatlimab is typically continued until disease progression or unacceptable toxicity. (See <a class="local">'Nivolumab-relatlimab'</a> above.)</p><p class="headingAnchor" id="H1418515538"><span class="h2">Less preferred options</span></p><p class="headingAnchor" id="H4237497127"><span class="h3">Ipilimumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">Ipilimumab</a> is a monoclonal antibody directed against cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). The combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus ipilimumab is effective in patients with treatment-naïve disease. (See <a class="local">'Nivolumab plus ipilimumab (preferred)'</a> above.)</p><p>In initial randomized phase III trials, <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> monotherapy improved OS in patients with metastatic melanoma [<a href="#rid6">6,54-57</a>]. However, the role of single-agent ipilimumab has become more limited with the development of PD-1 inhibitors (<a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 2</a>), <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 3</a>)) that are more active than ipilimumab and have less toxicity in this patient population. (See <a class="local">'Pembrolizumab'</a> above and <a class="local">'Nivolumab'</a> above and  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p>In separate phase III trials, <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> was directly compared with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> (KEYNOTE-006) and <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> (CheckMate 067) as single agents. In these trials, the overall toxicities associated with nivolumab or pembrolizumab were less frequent and severe than those associated with ipilimumab. Nivolumab and pembrolizumab were also discontinued less frequently for toxicity than ipilimumab, but with differing side effect profiles. Further results of these studies are discussed above. (See <a class="local">'Pembrolizumab'</a> above and <a class="local">'Toxicity'</a> above.)</p><p class="headingAnchor" id="H1172141888"><span class="h3">Chemotherapy</span><span class="headingEndMark"> — </span>In the era of checkpoint inhibitor immunotherapy, the role of chemotherapy in patients with metastatic melanoma is limited. Indications for chemotherapy in metastatic melanoma are discussed separately. (See  <a class="medical medical_review" href="/d/html/15406.html" rel="external">"Cytotoxic chemotherapy for metastatic melanoma"</a>.)</p><p class="headingAnchor" id="H262059967"><span class="h1">ASSESSING TREATMENT RESPONSE</span></p><p class="headingAnchor" id="H601233049"><span class="h2">Patterns of response</span><span class="headingEndMark"> — </span>In patients with metastatic melanoma receiving checkpoint inhibitor immunotherapy, evaluating treatment response requires an understanding of the distinct patterns of response seen with immunotherapy, which differ from those seen with chemotherapy or molecularly targeted agents in several important respects:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients may have a transient worsening of disease, manifested either by progression of known lesions or the appearance of new lesions, before the disease stabilizes or tumor regresses  (<a class="graphic graphic_diagnosticimage graphicRef103343" href="/d/graphic/103343.html" rel="external">image 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with interval tumor growth on restaging imaging studies obtained 8 to 12 weeks after initiating therapy who are <strong>asymptomatic</strong> or those who exhibit improved disease-related symptoms and/or a decline in serum lactase dehydrogenase (LDH) levels, some caution should be taken in discontinuing therapy early. In the absence of symptomatic progression, a short-term follow-up imaging study (after an additional six to eight weeks) to confirm disease status is reasonable [<a href="#rid58">58</a>]. (See <a class="local">'Imaging studies'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with interval tumor growth on restaging imaging studies obtained 8 to 12 weeks after initiating therapy who exhibit new or persistent symptoms (<strong>symptomatic</strong> <strong>disease</strong>) or rising LDH likely have true progressive disease [<a href="#rid59">59</a>]. We do not continue therapy beyond disease progression in these patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiographic responses can take longer to become apparent compared with other systemic therapies, such as chemotherapy or targeted therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients who do not meet criteria for objective response can have prolonged periods of stable disease that are clinically significant. In some of these patients, positron emission tomography (PET) computed tomography (CT) scans or tumor biopsies may show no evidence of residual tumor.</p><p></p><p>Immunotherapy response criteria have been developed to properly recognize these patterns of response and are discussed separately  (<a class="graphic graphic_table graphicRef107302" href="/d/graphic/107302.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Immunotherapy response criteria'</a>.)</p><p class="headingAnchor" id="H748927970"><span class="h2">Imaging studies</span><span class="headingEndMark"> — </span>Options for imaging patents to assess treatment response include CT and fludeoxyglucose (FDG)-PET-CT. PET-CT may be problematic early on in treatment, as an active immune response against tumor can increase the standardized uptake value (SUV), creating a false impression of disease progression. However, later in the treatment process (after approximately one year), a PET-CT provides a better assessment of treatment response to checkpoint inhibitor immunotherapy compared with CT, as it can identify complete metabolic responses (eg, residual tumor lesions on CT scans that are no longer FDG-avid) [<a href="#rid60">60</a>]. Such complete metabolic responses correlate with prolonged progression-free survival (PFS) [<a href="#rid61">61,62</a>] and melanoma-specific survival [<a href="#rid51">51</a>]. These data are consistent with the durable treatment-free survival observed with immunotherapy in other studies. (See <a class="local">'What is the optimal duration of immunotherapy?'</a> above and <a class="local">'Treatment-free survival'</a> below.)</p><p class="headingAnchor" id="H1903182088"><span class="h1">TREATMENT-FREE SURVIVAL</span></p><p class="headingAnchor" id="H4147370345"><span class="h2">Nivolumab plus ipilimumab</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> extends treatment-free survival (ie, the time from immunotherapy cessation to subsequent therapy initiation or death) compared with nivolumab or ipilimumab as single agents.</p><p>In a long-term follow-up phase III trial (Checkmate 067), at median follow-up of 81 months, among patients assigned to <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, 36 percent (112 of 314 patients) were alive and treatment free at 6.5 years, compared with 27 percent of those receiving nivolumab (84 of 316 patients) and 9 percent of those receiving ipilimumab (27 of 315 patients) [<a href="#rid11">11,12</a>]. Median treatment-free survival was approximately 28 months for the combination versus 2 months each for single-agent nivolumab and ipilimumab.</p><p>Similar promising results have been observed in other studies. In a combined analysis of the CheckMate 067 and CheckMate 069 trials, combination immunotherapy improved treatment-free survival relative to either single-agent <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> or <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> [<a href="#rid17">17,63</a>]. Among 1077 patients with advanced or metastatic melanoma treated with nivolumab and ipilimumab, more patients who received nivolumab plus ipilimumab were treatment free at three years of follow-up (47 percent) compared with those who received nivolumab or ipilimumab (37 and 15 percent, respectively). Mean treatment-free survival at three years was also greater for the combination (11 months) than for nivolumab or ipilimumab alone (five and nine months, respectively).</p><p class="headingAnchor" id="H3665946268"><span class="h1">SUBSEQUENT THERAPY</span><span class="headingEndMark"> — </span>Most patients with <em>BRAF</em> wild-type metastatic melanoma who receive checkpoint inhibitor immunotherapy will experience extended durable responses to therapy. However, others may demonstrate progressive disease. The choice of subsequent therapy in these patients is based on clinical factors such as prior therapies received as well as patient performance status  (<a class="graphic graphic_table graphicRef72901" href="/d/graphic/72901.html" rel="external">table 5</a>), comorbidities, goals, and preferences. Patients should be encouraged to enroll in clinical trials, where available.</p><p class="headingAnchor" id="H6330911"><span class="h2">Prior treatment with nivolumab plus ipilimumab</span><span class="headingEndMark"> — </span>For patients with <em>BRAF</em> wild-type disease who have progressed on combination therapy with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, we offer enrollment in clinical trials, where available. Further data on investigational agents being evaluated in patients with treatment-refractory melanoma are discussed separately. (See <a class="local">'Investigational agents'</a> below and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Investigational options'</a>.)</p><p>Patients may also have their tumors evaluated for actionable mutations (other than <em>BRAF</em>)<em> </em>for which standard therapies are available. Subsequent therapy for patients with metastatic melanoma harboring other actionable mutations are discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Other molecular alterations'</a>.)</p><p>For those who are ineligible for clinical trials and have no actionable mutations, options include <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a> [<a href="#rid64">64</a>], high-dose interleukin 2 [<a href="#rid65">65</a>], and chemotherapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nivolumab-relatlimab</strong> – <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">Nivolumab-relatlimab</a> was evaluated in a phase I/II trial (RELATIVITY-020) of 518 patients with advanced melanoma who had progressed on programmed cell death receptor 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor therapy [<a href="#rid64">64</a>]. This study included a subgroup of 354 patients who had progressed on at most one line of immunotherapy (including 40 percent also treated in combination with a CTLA-4 inhibitor therapy such as <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>). Within this subgroup, at minimum follow-up of 19 months, the objective response rate was 12 percent, and the median duration of response was not reached. Progression-free survival (PFS) at six months was 29 percent. Treatment was also well tolerated, with a grade ≥3 toxicity rate of 15 percent.</p><p></p><p class="bulletIndent1">The use of <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a> as initial therapy in metastatic melanoma is discussed above. (See <a class="local">'Nivolumab-relatlimab'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-dose IL-2 or chemotherapy</strong> – The use of these agents in patients with metastatic melanoma is discussed separately. (See  <a class="medical medical_review" href="/d/html/15407.html" rel="external">"Interleukin 2 and experimental immunotherapy approaches for advanced melanoma"</a> and  <a class="medical medical_review" href="/d/html/15406.html" rel="external">"Cytotoxic chemotherapy for metastatic melanoma"</a>.)</p><p></p><p class="headingAnchor" id="H1882124296"><span class="h2">Prior treatment with nivolumab-relatlimab</span><span class="headingEndMark"> — </span>For patients with <em>BRAF</em> wild-type disease who have progressed on <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a>, we offer subsequent therapy with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, using a similar approach to those who progress on single-agent PD-1 inhibitors. Although observational studies in patients with advanced melanoma suggest that regimens involving ipilimumab are less active following initial treatment with nivolumab-relatlimab [<a href="#rid66">66</a>], further prospective studies are necessary. Patients may also be offered enrollment in clinical trials, where available. (See <a class="local">'Prior treatment with single-agent PD-1 inhibitors (including adjuvant therapy)'</a> below.)</p><p class="headingAnchor" id="H3043318301"><span class="h2">Prior treatment with single-agent PD-1 inhibitors (including adjuvant therapy)</span></p><p class="headingAnchor" id="H1415740897"><span class="h3">Nivolumab plus ipilimumab</span><span class="headingEndMark"> — </span>For patients with <em>BRAF</em> wild-type metastatic melanoma who have progressed on single-agent programmed cell death receptor 1 (PD-1) inhibitors (either in the adjuvant or metastatic setting) and have no other actionable mutations, we suggest the combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef130970" href="/d/graphic/130970.html" rel="external">table 1</a>) rather than other available agents. Patients may alternatively be enrolled in clinical trials, where available. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Investigational options'</a>.)</p><p>For patients with <em>BRAF</em> wild-type disease and resistance to PD-1 inhibitor immunotherapy, subsequent therapy with the combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> improves PFS and objective response rates compared with single-agent ipilimumab, based on data from randomized trials [<a href="#rid67">67,68</a>] and observational studies [<a href="#rid69">69,70</a>]. In an open-label phase II trial (SWOG 1616), 92 patients with unresectable or metastatic melanoma who progressed on single-agent PD-1 or PD-L1 inhibitors and without prior exposure to a cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitor (eg, ipilimumab) were randomly assigned in a 3:1 ratio to either nivolumab plus ipilimumab for four cycles followed by maintenance nivolumab for up to two years  (<a class="graphic graphic_table graphicRef130970" href="/d/graphic/130970.html" rel="external">table 1</a>) or single-agent ipilimumab (3 mg/kg every three weeks for four cycles) [<a href="#rid68">68</a>]. This study also enrolled patients who progressed on single agent PD-1 or PD-L1 inhibitors in the adjuvant setting. </p><p>In preliminary results, at median follow-up of 25 months, compared with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus ipilimumab improved PFS (six-month PFS 34 versus 13 percent, hazard ratio [HR] 0.63, 90% CI 0.41-0.97) [<a href="#rid68">68</a>]. Overall survival (OS) was similar between the two treatment arms (one-year OS 63 versus 57 percent, HR 0.94, 90% CI 0.45-1.62). Objective response rates were higher for the combination compared with ipilimumab (28 versus 9 percent). Grade ≥3 toxicity rates were also higher for nivolumab plus ipilimumab compared with ipilimumab alone (57 versus 35 percent) but consistent with known safety profiles of these agents.</p><p class="headingAnchor" id="H2226409966"><span class="h3">What is the role of tumor-infiltrating lymphocytes?</span><span class="headingEndMark"> — </span>In patients with metastatic melanoma (regardless of <em>BRAF</em> mutation status) who progress on a PD-1 inhibitor either in the adjuvant or metastatic setting, therapy with tumor-infiltrating lymphocytes (TILs) improved PFS compared with single-agent <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in a phase III trial [<a href="#rid71">71</a>]. While promising, the use of TILs remains investigational, and we await regulatory approval prior to incorporating this approach into routine clinical practice. </p><p>TILs are a personalized type of adoptive cell therapy (ACT) in which an autologous infusion of T-cells are produced and expanded ex vivo from a tumor specimen obtained via metastasectomy. Patients subsequently receive nonmyeloablative (NMA) lymphodepleting chemotherapy (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>) and a single infusion of TILs, followed by the administration of high-dose interleukin-2 (IL-2) to enhance in vivo T-cell expansion. Further details on the mechanism of TILs, NMA lymphodepletion regimens, and IL-2 are discussed separately. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Manipulating T cells'</a> and  <a class="medical medical_review" href="/d/html/3557.html" rel="external">"Preparative regimens for hematopoietic cell transplantation", section on 'NMA and RIC regimens'</a> and  <a class="medical medical_review" href="/d/html/2812.html" rel="external">"Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines", section on 'Interferon and interleukin-2'</a> and  <a class="medical medical_review" href="/d/html/15407.html" rel="external">"Interleukin 2 and experimental immunotherapy approaches for advanced melanoma"</a>.)</p><p>Initial clinical studies demonstrated the efficacy of TILs in metastatic melanoma [<a href="#rid72">72-78</a>], including a phase II trial of lifileucel in patients whose disease was previously treated with immunotherapy and BRAF plus MEK inhibitors [<a href="#rid79">79</a>]. Based on these data, TILs were directly compared with single-agent <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in a randomized, open-label phase III trial of 168 patients with advanced unresectable or metastatic cutaneous melanoma [<a href="#rid71">71</a>]. All patients had no prior exposure to ipilimumab, and a majority had disease refractory to PD-1 inhibitors either in the adjuvant or metastatic setting (86 percent). </p><p>At median follow-up of 33 months, compared with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, data for TILs were as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Total study population</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Higher PFS (median PFS 7 versus 3 months, HR 0.50, 95% CI 0.35-0.72 per RECIST criteria; median six versus three months, HR 0.56, 95% CI 0.39-0.79 per immune-related response criteria).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although data are immature, a nonstatistically significant trend towards higher OS (median 26 versus 19 months; HR 0.83, 95% CI 0.54-1.27). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Higher objective (49 versus 21 percent per RECIST criteria; 50 versus 20 percent per immune-related response criteria) and complete (20 versus 7 percent per RECIST criteria) response rates. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment-related toxicity for TILs was mainly related to the lymphodepleting chemotherapy and IL-2 infusions. Grade ≥3 toxicity rates were higher for TILs versus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> (100 versus 57 percent) mainly due to grade 3 to 4 neutropenia from the lymphodepleting chemotherapy regimen. However, treatment-related serious adverse events were lower for TILs versus ipilimumab (15 versus 27 percent). Health-related quality of life and physical and emotional functioning were overall improved with TILs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>BRAF </em></strong><strong>wild-type disease</strong> – Among the 95 patients with <em>BRAF</em> wild-type disease, TILs improved PFS over <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> (HR 0.53, 95% CI 0.34-0.84). Further details of the efficacy of TILs in those with <em>BRAF</em> mutant metastatic melanoma are discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Adoptive cell therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prior therapy</strong> – A PFS benefit for TILs was demonstrated regardless of prior therapy (none, adjuvant therapy with a PD-1 inhibitor, or initial systemic therapy with a PD-1 inhibitor). </p><p></p><p class="headingAnchor" id="H4104360519"><span class="h3">Other approaches</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pembrolizumab</strong><strong> plus </strong><strong>ipilimumab</strong> — <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> is clinically effective in patients with disease refractory to single-agent PD-1 inhibitors, with clinical responses seen in up to one-third of patients [<a href="#rid80">80,81</a>]. However, the use of this combination remains investigational since it does not have regulatory drug approval in metastatic melanoma. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No role for PD-1 inhibitor rechallenge</strong> — We do not retreat patients with single-agent PD-1 inhibitors, as data suggest minimal clinical efficacy with this approach. </p><p></p><p class="bulletIndent1">In the second part of a placebo-controlled phase III trial (KEYNOTE-054) of adjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> for resected Stage III melanoma, patients with disease recurrence were treated with pembrolizumab at 200 mg every three weeks for a maximum of two years [<a href="#rid82">82</a>]. Patients who received adjuvant pembrolizumab and recurred six months or more after completing one year of adjuvant therapy were rechallenged with pembrolizumab, and those who received placebo crossed over to pembrolizumab. In preliminary results, among the 20 patients rechallenged with pembrolizumab, response rates were limited and median PFS was four months.</p><p></p><p class="bulletIndent1">By contrast, among the 155 patients who crossed over to <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, the objective response rate was 39 percent, and three-year PFS was 32 percent [<a href="#rid82">82</a>]. These data are comparable to the responses seen in patients with treatment-naïve metastatic disease treated with pembrolizumab. (See <a class="local">'Pembrolizumab'</a> above.)</p><p></p><p class="bulletIndent1">Further details on this study and the use of adjuvant <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> in resected cutaneous melanoma are discussed separately. (See  <a class="medical medical_review" href="/d/html/7615.html" rel="external">"Adjuvant and neoadjuvant therapy for cutaneous melanoma", section on 'Adjuvant pembrolizumab'</a>.)</p><p></p><p class="headingAnchor" id="H3095574978"><span class="h2">Prior treatment with single-agent ipilimumab</span><span class="headingEndMark"> — </span>For patients who progress on single-agent <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, we offer single-agent PD-1 inhibitors such as <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 3</a>) or <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 2</a>), as these agents were both superior to ipilimumab in randomized trials [<a href="#rid7">7,8,46</a>]. However, such patients are rare since initial therapy with ipilimumab is less preferred due to toxicity profile and the availability of other effective treatments. (See <a class="local">'Ipilimumab'</a> above.)</p><p class="headingAnchor" id="H2176923483"><span class="h1">INVESTIGATIONAL AGENTS</span><span class="headingEndMark"> — </span>Other systemic therapies have been evaluated in patients with metastatic melanoma, and their use remains investigational. Further prospective studies are necessary.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pembrolizumab</strong><strong> plus </strong><strong>ipilimumab</strong><strong> </strong>– There is no established role for the combination of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> as initial therapy in patients with advanced or metastatic melanoma, mostly due to lack of randomized trials. Nonetheless, early-phase studies (KEYNOTE-129) show robust efficacy and suggest less toxicity than what has previously been observed with standard-dose <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus ipilimumab [<a href="#rid83">83,84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pembrolizumab</strong><strong> plus </strong><strong>lenvatinib</strong> – The combination of the programmed cell death 1 protein (PD-1) inhibitor <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> with the vascular endothelial growth factor receptor inhibitor <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> has efficacy in patients who have progressed on immunotherapy with a PD-1/programmed cell death ligand 1 (PD-L1) inhibitor alone or in combination with a cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitor. Pembrolizumab and lenvatinib remains an investigational option, and further studies are necessary before incorporating this combination into routine clinical practice.</p><p></p><p class="bulletIndent1">This combination was evaluated in an open-label, single arm trial (LEAP-004) of 103 patients with immunotherapy-refractory, unresectable, or metastatic melanoma [<a href="#rid85">85</a>]. At median follow-up of 15 months, in the entire study population, the overall response rate was 21 percent, including complete and partial response rates of 3 and 18 percent; the median duration of response was 8 months. The median progression-free survival (PFS) and overall survival (OS) were 4 and 14 months, respectively. Among the subset of 30 patients previously treated with a PD-1/L1 and CTLA-4 doublet, the ORR was 33 percent. However, since this patient population was selected for resistance to checkpoint inhibitor immunotherapy (which has been associated with elevated levels of lactate dehydrogenase [LDH], an indirect measure of tumor hypoxia), it is possible that much of the clinical activity from this combination is driven primarily by <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GM-CSF plus immunotherapy </strong>– In a randomized phase II trial (E1608), the addition of granulocyte-macrophage colony-stimulating factor (GM-CSF) to high doses of <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> improved OS and decreased pulmonary and gastrointestinal toxicity [<a href="#rid86">86</a>]; these results require further prospective validation. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Combining or sequencing immunotherapy with other therapies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiome composition and fecal microbiota transplantation </strong>– Data suggest that gastrointestinal microbiome composition (and therapies that influence it) may be associated with response to immunotherapy in melanoma [<a href="#rid87">87-89</a>]. As an example, in early-phase clinical trials, fecal microbiota transplantation (FMT) overcame disease resistance and promoted treatment responses in patients with metastatic melanoma who progressed on immunotherapy [<a href="#rid90">90,91</a>]. Alternatives to FMT are also being investigated, such as microbial consortia (multi-species mixtures of cultivated microbes) [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intralesional T-VEC plus immunotherapy</strong> – Although the combination of the oncolytic virus <a class="drug drug_general" data-topicid="104964" href="/d/drug information/104964.html" rel="external">talimogene laherparepvec</a> (T-VEC) with immunotherapy demonstrated clinical efficacy in early-phase clinical trials of patients with advanced unresectable and metastatic melanoma [<a href="#rid93">93-97</a>], a randomized phase III trial showed no overall survival benefit for this approach [<a href="#rid98">98</a>].</p><p></p><p class="bulletIndent1">The use of T-VEC in patients with cutaneous melanoma is discussed separately. (See  <a class="medical medical_review" href="/d/html/7607.html" rel="external">"Cutaneous melanoma: Management of local recurrence", section on 'Talimogene laherparepvec'</a> and  <a class="medical medical_review" href="/d/html/7608.html" rel="external">"Cutaneous melanoma: In-transit metastases", section on 'Intralesional therapy (T-VEC)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other agents </strong>– Other investigational systemic therapies, including antiangiogenic therapy and agents effective in patients with <em>BRAF</em> mutant disease, are discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Investigational options'</a>.)</p><p></p><p class="headingAnchor" id="H3872317081"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H2596579297"><span class="h2">Brain metastases</span><span class="headingEndMark"> — </span>For select patients with untreated brain metastases, data indicate that immunotherapy has a role in the multidisciplinary approach to patient management. (See  <a class="medical medical_review" href="/d/html/7611.html" rel="external">"Management of brain metastases in melanoma"</a>.)</p><p class="headingAnchor" id="H96058376"><span class="h2">Noncutaneous melanoma</span><span class="headingEndMark"> — </span>A majority of patients with metastatic noncutaneous (ie, mucosal and uveal) melanoma lack <em>BRAF</em> mutations. (See  <a class="medical medical_review" href="/d/html/16540.html" rel="external">"The molecular biology of melanoma", section on 'Genetic abnormalities in melanoma'</a>.)</p><p>The approach to systemic therapy for these patients is discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mucosal melanoma</strong> (see  <a class="medical medical_review" href="/d/html/138441.html" rel="external">"Treatment of metastatic mucosal melanoma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uveal melanoma</strong> (see  <a class="medical medical_review" href="/d/html/113047.html" rel="external">"Metastatic uveal melanoma"</a>)</p><p></p><p class="headingAnchor" id="H831344311"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118501.html" rel="external">"Society guideline links: Melanoma screening, prevention, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H177442841"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Available immunotherapy agents </strong>– For patients with metastatic melanoma lacking a <em>BRAF</em> V600 mutation, there have been important advances in systemic therapy, such as checkpoint inhibitor immunotherapy. Available options for immunotherapy include agents that inhibit cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) such as <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, those that inhibit lymphocyte-activation gene 3 (LAG-3) such relatlimab, and those that inhibit the programmed cell death receptor 1 (PD-1) such as <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 2</a>) and <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 3</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment-naïve patients with </strong><strong><em>BRAF</em></strong><strong> wild-type disease </strong>– For treatment-naïve patients with <em>BRAF</em> wild-type disease, we recommend initial treatment with immunotherapy that includes a PD-1 inhibitor (<a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>) rather than other systemic agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Treatment-naive patients'</a> above and <a class="local">'Benefits of immunotherapy over chemotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with features of aggressive disease</strong> – For patients with aggressive disease, we suggest using combination immunotherapy with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef130970" href="/d/graphic/130970.html" rel="external">table 1</a>) rather than a single-agent PD-1 inhibitor or <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>)  (<a class="graphic graphic_algorithm graphicRef105384" href="/d/graphic/105384.html" rel="external">algorithm 1</a>). Clinical features that suggest aggressive disease include elevated lactate dehydrogenase (LDH); acral primary; and brain metastases, liver metastases, and/or other symptomatic systemic metastases. Nivolumab plus ipilimumab showed a nonstatistically significant trend for improved progression-free survival (PFS) and overall survival (OS), and improved treatment-free survival in this population where salvage therapy may not be available. (See <a class="local">'Nivolumab plus ipilimumab (preferred)'</a> above and <a class="local">'Treatment-free survival'</a> above.)</p><p></p><p class="bulletIndent2">For those who are anticipated to not tolerate the toxicities of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, we suggest <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a> rather than single-agent PD-1 inhibitors (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>), as this agent improved PFS over single-agent nivolumab in a randomized trial and has a more favorable toxicity profile than nivolumab plus ipilimumab. (See <a class="local">'Nivolumab-relatlimab'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients lacking features of aggressive disease</strong> – For patients who lack features of aggressive disease, we suggest <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a> rather than single-agent PD-1 inhibitors (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Nivolumab-relatlimab (preferred)'</a> above.)</p><p></p><p class="bulletIndent2">For those who are anticipated to not tolerate the potential toxicities of combination immunotherapy (ie, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> or <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a>) we offer a single-agent PD-1 inhibitor as a suitable alternative  (<a class="graphic graphic_algorithm graphicRef105384" href="/d/graphic/105384.html" rel="external">algorithm 1</a>). Options include <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 2</a>) or nivolumab  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 3</a>). (See <a class="local">'Pembrolizumab'</a> above and <a class="local">'Nivolumab'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>What is the optimal duration of immunotherapy? </strong>– For patients receiving single-agent PD-1 inhibitor immunotherapy (either as monotherapy or maintenance therapy after <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>) with either a partial response or stable disease, we typically administer treatment for a maximum of two years in the absence of toxicity. (See <a class="local">'What is the optimal duration of immunotherapy?'</a> above.)</p><p></p><p class="bulletIndent2">However, for those with a complete response, single-agent immunotherapy may be discontinued after at least six months of therapy have been completed if the complete response has been confirmed on at least two sets of restaging imaging studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with a </strong><strong><em>BRAF </em></strong><strong>V600 mutation</strong> – For patients with a <em>BRAF </em>V600<em> </em>mutation, options for initial therapy include <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a>, single-agent PD-1 inhibitors, and targeted therapy with BRAF plus MEK inhibitors  (<a class="graphic graphic_algorithm graphicRef105384" href="/d/graphic/105384.html" rel="external">algorithm 1</a>). Further treatment details in this population are discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'BRAF V600 mutant disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessing treatment response </strong>– In patients with metastatic melanoma receiving checkpoint inhibitor immunotherapy, specific immunotherapy response criteria have been developed to assess treatment response  (<a class="graphic graphic_table graphicRef107302" href="/d/graphic/107302.html" rel="external">table 4</a>). (See <a class="local">'Assessing treatment response'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior </strong><strong>nivolumab</strong><strong> plus </strong><strong>ipilimumab</strong> – For patients with <em>BRAF</em> wild-type disease who have progressed on <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, we evaluate their tumors for actionable mutations (other than <em>BRAF</em>) and offer enrollment in clinical trials, where available. (See <a class="local">'Prior treatment with nivolumab plus ipilimumab'</a> above and <a class="local">'Investigational agents'</a> above.)</p><p></p><p class="bulletIndent2">For patients who are ineligible for clinical trials and have no actionable mutations, options include <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a>, high-dose interleukin 2, and chemotherapy. (See <a class="local">'Prior treatment with nivolumab plus ipilimumab'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior </strong><strong>nivolumab-relatlimab</strong> – For patients who have progressed on <a class="drug drug_general" data-topicid="135303" href="/d/drug information/135303.html" rel="external">nivolumab-relatlimab</a>, we offer <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, using a similar approach to those who progress on single-agent PD-1 inhibitors. Clinical trial enrollment is encouraged, where available. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior single-agent PD-1 inhibitors</strong> – For those who have progressed on single-agent PD-1 inhibitors (either in the adjuvant or metastatic setting) and have no other actionable mutations, we suggest the combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef130970" href="/d/graphic/130970.html" rel="external">table 1</a>) rather than other available agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We do not retreat these patients with single-agent PD-1 inhibitors, as data suggest minimal clinical efficacy with this approach. (See <a class="local">'Prior treatment with single-agent PD-1 inhibitors (including adjuvant therapy)'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809.</a></li><li><a class="nounderline abstract_t">Wellbrock C, Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol 2010; 80:561.</a></li><li><a class="nounderline abstract_t">Smalley KS, Sondak VK. Melanoma--an unlikely poster child for personalized cancer therapy. N Engl J Med 2010; 363:876.</a></li><li><a class="nounderline abstract_t">Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29:1239.</a></li><li><a class="nounderline abstract_t">Ascierto PA, Long GV, Robert C, et al. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncol 2019; 5:187.</a></li><li><a class="nounderline abstract_t">Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 2015; 33:1191.</a></li><li><a class="nounderline abstract_t">Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16:908.</a></li><li><a class="nounderline abstract_t">Hamid O, Puzanov I, Dummer R, et al. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer 2017; 86:37.</a></li><li><a class="nounderline abstract_t">Pires da Silva I, Ahmed T, McQuade JL, et al. Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. J Clin Oncol 2022; 40:1068.</a></li><li><a class="nounderline abstract_t">Dummer R, Corrie P, Gutzmer R, et al. First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401. J Clin Oncol 2023; 41:3917.</a></li><li><a class="nounderline abstract_t">Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2019; 381:1535.</a></li><li><a class="nounderline abstract_t">Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol 2022; 40:127.</a></li><li><a class="nounderline abstract_t">Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373:23.</a></li><li><a class="nounderline abstract_t">Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2017; 377:1345.</a></li><li><a class="nounderline abstract_t">Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016; 17:1558.</a></li><li><a class="nounderline abstract_t">Callahan MK, Kluger H, Postow MA, et al. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. J Clin Oncol 2018; 36:391.</a></li><li><a class="nounderline abstract_t">Regan MM, Werner L, Rao S, et al. Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol 2019; 37:3350.</a></li><li><a class="nounderline abstract_t">Lebbé C, Meyer N, Mortier L, et al. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. J Clin Oncol 2019; 37:867.</a></li><li><a class="nounderline abstract_t">Lebbe C, Meyer N, Mortier L, et al. Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511. J Clin Oncol 2021; 39;15S.</a></li><li><a class="nounderline abstract_t">Postow MA, Goldman DA, Shoushtari AN, et al. Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). J Clin Oncol 2022; 40:1059.</a></li><li><a class="nounderline abstract_t">Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122.</a></li><li><a class="nounderline abstract_t">Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J Clin Oncol 2017; 35:3807.</a></li><li><a class="nounderline abstract_t">Shoushtari AN, Friedman CF, Navid-Azarbaijani P, et al. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. JAMA Oncol 2018; 4:98.</a></li><li><a class="nounderline abstract_t">Weber JS, Gibney G, Sullivan RJ, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol 2016; 17:943.</a></li><li><a class="nounderline abstract_t">Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med 2022; 386:24.</a></li><li class="breakAll">Nivolumab-relatlimab: US Food and Drug Administration Label and Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761234s000lbl.pdf (Accessed on March 21, 2022).</li><li><a class="nounderline abstract_t">Long GV, Hodi FS, Lipson EJ, et al. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. NEJM Evid 2023; 2.</a></li><li><a class="nounderline abstract_t">Schadendorf D, Tawbi H, Lipson EJ, et al. Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial. Eur J Cancer 2023; 187:164.</a></li><li><a class="nounderline abstract_t">Lala M, Li TR, de Alwis DP, et al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur J Cancer 2020; 131:68.</a></li><li><a class="nounderline abstract_t">Strohbehn GW, Holleman R, Burns J, et al. Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation. JAMA Oncol 2022; 8:1663.</a></li><li><a class="nounderline abstract_t">Lala M, Akala O, Chartash E, et al. Pembrolizumab 400 mg Q6W dosing: First clinical outcomes data from Keynote-555 cohort B in metastatic melanoma patients. Cancer Res 2020; 80S: AACR #CT042.</a></li><li><a class="nounderline abstract_t">Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 2019; 30:582.</a></li><li><a class="nounderline abstract_t">Long GV, Dummer R, Hamid O, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol 2019; 20:1083.</a></li><li><a class="nounderline abstract_t">Ribas A, Hamid O, Daud A, et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA 2016; 315:1600.</a></li><li><a class="nounderline abstract_t">Daud AI, Wolchok JD, Robert C, et al. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol 2016; 34:4102.</a></li><li><a class="nounderline abstract_t">Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 2019; 20:1239.</a></li><li><a class="nounderline abstract_t">Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372:2521.</a></li><li><a class="nounderline abstract_t">Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017; 390:1853.</a></li><li><a class="nounderline abstract_t">Petrella TM, Robert C, Richtig E, et al. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. Eur J Cancer 2017; 86:115.</a></li><li><a class="nounderline abstract_t">Robert C, Carlino MS, McNeil C, et al. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. J Clin Oncol 2023; 41:3998.</a></li><li><a class="nounderline abstract_t">Carlino MS, Long GV, Schadendorf D, et al. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. Eur J Cancer 2018; 101:236.</a></li><li class="breakAll">Nivolumab: US Food and Drug Administration (FDA) Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s119lbl.pdf (Accessed on February 20, 2023).</li><li><a class="nounderline abstract_t">Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443.</a></li><li><a class="nounderline abstract_t">Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020.</a></li><li><a class="nounderline abstract_t">Topalian SL, Hodi FS, Brahmer JR, et al. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncol 2019; 5:1411.</a></li><li><a class="nounderline abstract_t">Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375.</a></li><li><a class="nounderline abstract_t">Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320.</a></li><li><a class="nounderline abstract_t">Long GV, Atkinson V, Ascierto PA, et al. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. Ann Oncol 2016; 27:1940.</a></li><li><a class="nounderline abstract_t">Robert C, Ribas A, Hamid O, et al. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol 2018; 36:1668.</a></li><li><a class="nounderline abstract_t">Jansen YJL, Rozeman EA, Mason R, et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol 2019; 30:1154.</a></li><li><a class="nounderline abstract_t">Ellebaek E, Schina A, Andersen R, et al. Clinical value of routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma. Int J Cancer 2022; 150:1870.</a></li><li><a class="nounderline abstract_t">Rubatto M, Fava P, Stanganelli I, et al. Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup. Eur J Cancer 2023; 187:25.</a></li><li><a class="nounderline abstract_t">Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455.</a></li><li><a class="nounderline abstract_t">Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711.</a></li><li><a class="nounderline abstract_t">Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517.</a></li><li><a class="nounderline abstract_t">Schadendorf D, Hodi FS, Robert C, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015; 33:1889.</a></li><li><a class="nounderline abstract_t">Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2017.</a></li><li><a class="nounderline abstract_t">Beaver JA, Hazarika M, Mulkey F, et al. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. Lancet Oncol 2018; 19:229.</a></li><li><a class="nounderline abstract_t">Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol 2016; 34:1510.</a></li><li><a class="nounderline abstract_t">Gibney GT, Zaemes J, Shand S, et al. PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma. J Immunother Cancer 2021; 9.</a></li><li><a class="nounderline abstract_t">Tan AC, Emmett L, Lo S, et al. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Ann Oncol 2018; 29:2115.</a></li><li><a class="nounderline abstract_t">Dimitriou F, Lo SN, Tan AC, et al. FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma. Ann Oncol 2022; 33:99.</a></li><li><a class="nounderline abstract_t">Mantia CM, Werner L, Stwalley B, et al. Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors. Melanoma Res 2022; 32:35.</a></li><li><a class="nounderline abstract_t">Ascierto PA, Lipson EJ, Dummer R, et al. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. J Clin Oncol 2023; 41:2724.</a></li><li><a class="nounderline abstract_t">Buchbinder EI, Dutcher JP, Daniels GA, et al. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J Immunother Cancer 2019; 7:49.</a></li><li><a class="nounderline abstract_t">Menzies AM, Pires da Silva I, Trojaniello C, et al. CTLA-4 Blockade Resistance after Relatlimab and Nivolumab. N Engl J Med 2022; 386:1668.</a></li><li><a class="nounderline abstract_t">Friedman CF, Spencer C, Cabanski CR, et al. Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. J Immunother Cancer 2022; 10.</a></li><li class="breakAll">Ari M. Vanderwalde, James Moon, Kari Kendra, Nikhil I. Khushalani, et al. S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy In: Proceedings of the 113th Annual Meeting of the American Association for Cancer Research; 2021 April 8-13; New Orleans LA. Philadelphia (PA): AACR; 2022. Abstract CT013. https://www.abstractsonline.com/pp8/#!/10517/presentation/20155 (Accessed on April 19, 2022).</li><li><a class="nounderline abstract_t">Zimmer L, Apuri S, Eroglu Z, et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer 2017; 75:47.</a></li><li><a class="nounderline abstract_t">Bowyer S, Prithviraj P, Lorigan P, et al. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br J Cancer 2016; 114:1084.</a></li><li><a class="nounderline abstract_t">Rohaan MW, Borch TH, van den Berg JH, et al. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N Engl J Med 2022; 387:2113.</a></li><li><a class="nounderline abstract_t">van den Berg JH, Heemskerk B, van Rooij N, et al. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. J Immunother Cancer 2020; 8.</a></li><li><a class="nounderline abstract_t">Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233.</a></li><li><a class="nounderline abstract_t">Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550.</a></li><li><a class="nounderline abstract_t">Ellebaek E, Iversen TZ, Junker N, et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med 2012; 10:169.</a></li><li><a class="nounderline abstract_t">Andersen R, Donia M, Ellebaek E, et al. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. Clin Cancer Res 2016; 22:3734.</a></li><li><a class="nounderline abstract_t">Dudley ME, Wunderlich JR, Yang JC, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002; 25:243.</a></li><li><a class="nounderline abstract_t">Pilon-Thomas S, Kuhn L, Ellwanger S, et al. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother 2012; 35:615.</a></li><li><a class="nounderline abstract_t">Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol 2021; 39:2656.</a></li><li><a class="nounderline abstract_t">Pires da Silva I, Ahmed T, Reijers ILM, et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol 2021; 22:836.</a></li><li><a class="nounderline abstract_t">Olson DJ, Eroglu Z, Brockstein B, et al. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol 2021; 39:2647.</a></li><li><a class="nounderline abstract_t">Eggermont AM, Meshcheryakov A, Atkinson V, et al. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. J Clin Oncol 2021; 39;15S.</a></li><li><a class="nounderline abstract_t">Long GV, Atkinson V, Cebon JS, et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol 2017; 18:1202.</a></li><li><a class="nounderline abstract_t">Carlino MS, Menzies AM, Atkinson V, et al. Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clin Cancer Res 2020; 26:5086.</a></li><li><a class="nounderline abstract_t">Arance A, de la Cruz-Merino L, Petrella TM, et al. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. J Clin Oncol 2023; 41:75.</a></li><li><a class="nounderline abstract_t">Hodi FS, Lee S, McDermott DF, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 2014; 312:1744.</a></li><li><a class="nounderline abstract_t">Lee KA, Thomas AM, Bolte LA, et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat Med 2022; 28:535.</a></li><li><a class="nounderline abstract_t">Spencer CN, McQuade JL, Gopalakrishnan V, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 2021; 374:1632.</a></li><li><a class="nounderline abstract_t">Eng L, Sutradhar R, Niu Y, et al. Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study. J Clin Oncol 2023; 41:3122.</a></li><li><a class="nounderline abstract_t">Davar D, Dzutsev AK, McCulloch JA, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 2021; 371:595.</a></li><li><a class="nounderline abstract_t">Baruch EN, Youngster I, Ben-Betzalel G, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 2021; 371:602.</a></li><li><a class="nounderline abstract_t">Spreafico A, Heirali AA, Araujo DV, et al. First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial). Ann Oncol 2023; 34:520.</a></li><li><a class="nounderline abstract_t">Puzanov I, Milhem MM, Minor D, et al. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. J Clin Oncol 2016; 34:2619.</a></li><li><a class="nounderline abstract_t">Ribas A, Dummer R, Puzanov I, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell 2017; 170:1109.</a></li><li><a class="nounderline abstract_t">Chesney J, Puzanov I, Collichio F, et al. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol 2018; 36:1658.</a></li><li><a class="nounderline abstract_t">Chesney J, Puzanov I, Collichio F, et al. Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. Br J Cancer 2019; 121:417.</a></li><li><a class="nounderline abstract_t">Long G, Dummer R, Johnson D, et al. Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma. J Immunother Cancer 2020; 8:A261 (suppl 3).</a></li><li><a class="nounderline abstract_t">Chesney JA, Ribas A, Long GV, et al. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. J Clin Oncol 2023; 41:528.</a></li></ol></div><div id="topicVersionRevision">Topic 15863 Version 161.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20818844" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Inhibition of mutated, activated BRAF in metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20350535" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : BRAF as therapeutic target in melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20818849" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Melanoma--an unlikely poster child for personalized cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21343559" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30422243" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25713437" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26115796" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28961465" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35143285" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37307514" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31562797" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34818112" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26027431" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28889792" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27622997" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29040030" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31498030" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30811280" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34928709" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23724867" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Nivolumab plus ipilimumab in advanced melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28841387" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28817755" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27269740" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34986285" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34986285" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37167764" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32305010" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36136314" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pembrolizumab 400 mg Q6W dosing: First clinical outcomes data from Keynote-555 cohort B in metastatic melanoma patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30715153" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31221619" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27092830" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27863197" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31345627" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25891173" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pembrolizumab versus Ipilimumab in Advanced Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28822576" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28987768" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37348035" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30096704" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30096704" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22658127" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24590637" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31343665" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25795410" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25399552" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Nivolumab in previously untreated melanoma without BRAF mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27405322" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29283791" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30923820" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35001363" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical value of routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37099946" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22658128" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20525992" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Improved survival with ipilimumab in patients with metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21639810" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25667295" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28359784" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29361469" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26951310" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34599027" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30137228" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34687894" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34855329" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36780608" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30777131" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35476655" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35074903" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35074903" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28214657" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27124339" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36477031" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32753545" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18809613" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21498393" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22909342" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27006492" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12000866" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22996367" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33979178" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33989557" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33945288" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28729151" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32605909" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35867951" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25369488" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35228751" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34941392" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36827626" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33542131" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33303685" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36863483" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27298410" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28886381" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28981385" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31353364" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35998300" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
